Overview A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG) Status: Recruiting Trial end date: 2026-09-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG. Phase: Phase 3 Details Lead Sponsor: Ionis Pharmaceuticals, Inc.